On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

The pharmaceutical company reported third-quarter earnings and sales that beat analysts’ expectations, boosted by ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy ...

As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

Investing.com -- Sanofi (EPA: SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

SNY posts strong third-quarter results, beating estimates for both earnings and sales. Shares rise in pre-market.

However, Novavax's shares recently dropped by about 20% in one day after it announced a clinical setback. The biotech's stock ...

Sanofi (SNYNF, SNY) said that the U.S. Food and Drug Administration has updated the label for FLUBLOK (Influenza Vaccine) to include ...